Cytarabine

Catalog No.S1648

Cytarabine Chemical Structure

Molecular Weight(MW): 243.22

Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

Size Price Stock Quantity  
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 14 Publications

3 Customer Reviews

  • Viability and CI vs Fa after 24-h exposure to cytarabine alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM (500 ng/ml for cytarabine; quadruplicates±s.e.m.).

    Leukemia, 2015, 29(8): 1702–1712. Cytarabine purchased from Selleck.

  • Cell cycle was analyzed using propidium iodide (PI) staining and flow cytometry. The plots show PI staining at the x-axis and cell counts at the y-axis. The graphs were prepared using ModFit LT™ software (Verity Software House). Nd: not detected, Ara-c:Cytarabine

    J Exp Clin Cancer Res, 2017, 36(1):22. Cytarabine purchased from Selleck.

  • Flow cytometry analysis for cell surface expression of CD11b shows time- and dose-dependent upregulation of the marker CD11b in MLL-rearranged leukemia cells treated with EPZ-5676 and Cytarabine(Ara-C) as single agents and in combination.

    J Pharmacol Exp Ther, 2014, 350(3): 646-56. Cytarabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.
Features The 1st of a series of cancer drugs that alters the sugar component of nucleosides.
Targets
DNA synthesis [1]
(CCRF-CEM cells)
16 nM
In vitro

Cytarabine (AraC) is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC50 of 16 nM. [1] Increasing concentrations of Cytarabine (IC50 of 0.69 μM) results in decreased metabolic activity of sensitive rat leukemic cell line RO/1, and the cell toxity can be highly enhanced by transfection with human wt dCK (IC50 of 0.037 μM) but not the inactive, alternatively spliced dCK forms. [2] Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse L1210 cells MVnDfZRwfG:6aXRCpIF{e2G7 NF3pXXo{KGSjeYO= MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBl\W:6eX71Z4xmd3OrZHWgZY5idG:pdXWtd4Vve2m2aY\lJI1wfXOnIFyxNlExKGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHQh[XO|YYmsJGlEPTB;MD60JI5ONg>? NFzjcFQyQTZ5NEmwNy=>
human CCRF-CEM cells NFLERWNEgXSxdH;4bYPDqGG|c3H5 MlLWN{Bl[Xm| Mk[0R5l1d3SxeHnjbZR6KGGpYXnud5Qh\GWxeInueYNt\W:|aXTlJIFv[WyxZ4XlMZNmdnOrdHn2[UBpfW2jbjDDR3JHNUOHTTDj[YxteyCjZoTldkA{KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVEhdk1w NV\UWlN[OTl4N{S5NFM>
human MCF7 cells MVLDfZRwfG:6aXRCpIF{e2G7 MWezJIRigXN? M2TSemN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGSnb4j5cpVkdGWxc3nk[UBidmGub3f1[U1{\W6|aYTpeoUhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUSgcm0v NIr6S5QyQTZ5NEmwNy=>
CCRF-CEM cell line MnvzSpVv[3Srb36gZZN{[Xl? MkPsTY5pcWKrdDD0bIUhemWybHnjZZRqd25ib3[gR2NTTi2FRV2gZ4VtdCCuaX7lJIlvKH[rdILvMEBGTDVyPUWgcm0v NUfxSXNIOTl7NUi5OC=>
human P12-ICHIKAWA cell M2jBOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXj0OXIyUW6qaXLpeIlwdiCxZjDoeY1idiCSMUKtTWNJUUuDV1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlU1KG6PLh?= MXzTRW5ITVJ?
human CCRF-CEM cells MWnDfZRwfG:6aXRCpIF{e2G7 MmLaOFghcA>? NFz6SHJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBES1KILVPFUUBk\WyuczDh[pRmeiB2ODDodpMh[nliY3XscEB1cXSncj3icJVmKGG|c3H5MEBGSzVyPUWuOlEhdk1w MXyxPVc1Ozh3OB?=
CCRF-CEM cell lines MXrGeY5kfGmxbjDhd5NigQ>? NILrW3Q4OiCq MUjDc45k\W62cnH0bY9vKHKncYXpdoVlKHSxIHnubIljcXRicnXwcIlk[XSrb36gc4YhS0OURj3DSW0h[2WubDDsbY5meyCkeTC1NEUh[W[2ZYKgO|IhcHJiaX7jeYJifGmxbjygSWQ2OD14IH7NMi=> NF;aN3gyPjV{MEK0
human CCRF-CEM cells MYDDfZRwfG:6aXRCpIF{e2G7 MnHTOFghcA>? MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDR3JHNUOHTTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkh[2WubITpeIVzNWKudXWgZZN{[XluIFnDOVA:PiCwTT6= Mlz4NlI2QDJ7OUG=
human SF268 cells NIfjbVdEgXSxdH;4bYPDqGG|c3H5 M3HPUGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNHOjZ6IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD15Lk[4JI5ONg>? NEDwR5QyQTN2NUW4NS=>
MOLT-4 human leukemic lymphoblastoid cell lines Ml;aR5l1d3SxeHnjxsBie3OjeR?= NFL6[4xEgXSxdH;4bYNqfHliYXfhbY5{fCCPT1zUMVQhcHWvYX6gcIV2c2WvaXOgcJlueGixYnzhd5RwcWRiY3XscEBtcW6nczygTWM2OD1zMDDuUU4> NYm2dHFoPjh{N{W0Oi=>
human 697 cell M3\tUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGjTRnNKdmirYnn0bY9vKG:oIHj1cYFvKDZ7NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlYhdk1w NH\YfFJUSU6JRWK=
human ES1 cell NUHEV49sT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYjJcohq[mm2aX;uJI9nKGi3bXHuJGVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF{Lkm3JI5ONg>? MXnTRW5ITVJ?
CCRF-CEM human leukemic lymphoblastoid cell lines NH;le3ZEgXSxdH;4bYPDqGG|c3H5 NHvudVREgXSxdH;4bYNqfHliYXfhbY5{fCCFQ2LGMWNGVSCqdX3hckBt\XWtZX3pZ{BtgW2yaH;icIF{fG:rZDDj[YxtKGyrbnXzMEBKSzVyPUKwJI5ONg>? M2H6OlY5Ojd3NE[=
P388 murine cell lines NFSxT4NHfW6ldHnvckBie3OjeR?= NVTab5N2PzJiaB?= M3XMN3Rp\SClb33wc5Vv\CC5YYOgeIV{fGWmIHnuJJZqfHKxIH\vdkBidnSrdIXtc5Ih[WO2aY\peJkpPTBnIHnubIljcXSrb36gc4YhfHWvb4KgZ4VtdCCpcn;3eIgqKGGpYXnud5QhfGinIGCzPFghdXW{aX7lJINmdGxibHnu[ZMh[W[2ZYKgO|IhcG:3coOsJGlFPTB;MkCgcm0v NHLnT4s{PjJ3N{G0
L1210 murine cell lines NHjLUYxHfW6ldHnvckBie3OjeR?= MmfqO|IhcA>? NYjvbG9uXGinIHPvcZBwfW6mIIfhd{B1\XO2ZXSgbY4hfmm2cn:g[o9zKGGwdHn0eY1weiCjY4Tpeol1gSh3MDWgbY5pcWKrdHnvckBw\iC2dX3vdkBk\WyuIHfyc5d1cCliYXfhbY5{fCC2aHWgUFEzOTBibYXybY5mKGOnbHygcIlv\XNiYX\0[ZIhPzJiaH;1dpMtKEmGNUC9NlAhdk1w NH\nRnI{PjJ3N{G0
human HEL cell NWrJdm82T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1rJO2lvcGmkaYTpc44hd2ZiaIXtZY4hUEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkCuOVIhdk1w NX7tUpp{W0GQR1XS
human CCRF-CEM/C2 cells NWDEPG1oS3m2b4TvfIlkyqCjc4PhfS=> M2jKeFQ5KGh? M2XVPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNEWkZvQ1XNM2MzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDj[YxtKHSrdHXyMYJtfWViYYPzZZktKEWFNUC9NlIvQCCwTT6= MU[xPVc1Ozh3OB?=
mouse L1210 cells MUHDfZRwfG:6aXRCpIF{e2G7 NYf6UVIxPDhiaB?= NEXTc4dEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBNOTJzMDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA1QCCqcoOsJGlEPTB;MD6wNlQh|ryPLh?= M2PuTlIxODByNEG4
human CEM cells MljzR5l1d3SxeHnjxsBie3OjeR?= M3jDO|Q5KGh? NInXZ2dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1iY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgOFghcHK|LDDJR|UxRTBwMEK0JO69VS5? M3XIPVIxODByNEG4
human 2209-23 cells MX\Qdo9tcW[ncnH0bY9vKGG|c3H5 M1e4[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iMkKwPU0zOyClZXzsd{BjgSCdM1jdeIh6dWmmaX7lJIlv[2:{cH;yZZRqd25ic3PpcpRqdGyjdHnvckBxem:6aX3peJkh[XO|YYmsJGlEPTB;MD6wNlkh|ryP NV\tdYF1OTlyNUW0PFI>
human CHP-212 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4fIXGlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM{NjR5IH7NMi=> M3rBbHNCVkeHUh?=
human CTB-1 cell NH\KN4xIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH3HfotKdmirYnn0bY9vKG:oIHj1cYFvKEOWQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|QvOyCwTR?= NYrMWohEW0GQR1XS
human A427 cell NGruPHlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmnWTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{SuOFkhdk1w MkPHV2FPT0WU
human MOLT-16 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIO3XZdKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Pi5yNzDuUU4> M{jsXXNCVkeHUh?=
human MCF7 1K cells NY\QNFZjS3m2b4TvfIlkyqCjc4PhfS=> NGHG[GE{KGSjeYO= NETpWJFEgXSxdH;4bYNqfHliYXfhbY5{fCCmZX;4fY52[2ynb4Pp[IUh[W6jbH;neYUuemW|aYP0ZY51KGi3bXHuJG1ETjdiMVugZ4VtdHNib4\ldoV5eHKnc4Ppcochemmkb371Z4xmd3SrZHWgdoVlfWO2YYPlJIFnfGW{IEOg[IF6eyCkeTDNWHQh[XO|YYmsJGlEPTB;NECgcm0v NHvaOVIyQTZ5NEmwNy=>
human MC-IXC cell MlrnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mof0TY5pcWKrdHnvckBw\iCqdX3hckBOSy2LWFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20NU41OSCwTT6= NU\3N5R[W0GQR1XS
human BHT-101 cell MkLRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn7mTY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFEvPzZibl2= MmHMV2FPT0WU
human K5 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIPSe4hKdmirYnn0bY9vKG:oIHj1cYFvKEt3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NEOuNkBvVQ>? M4DxcnNCVkeHUh?=
parent promyelocytic leukemia cell line NYKxWIF7TnWwY4Tpc44h[XO|YYm= MWrBcpRq[2GwY3XyJIFkfGm4aYT5JJdieyCndnHseYF1\WRiZn;yJJRp\SClb33wc5Vv\CCjZ3HpcpN1KHCjcnXueEBxem:veXXsc4N6fGmlIHzleYtmdWmjIHPlcIwhdGmwZTCoTGwuPjBvR1jQVnQsN2SFSzupMEBGTDVyPUS3JI5ONg>? NYTzdoo5OzB{N{OyPS=>
human HL60 cells MWDDfZRwfG:6aXRCpIF{e2G7 MoGzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgZ4VtdHSrdHXyMYJtfWViYYPzZZktKEmFNUC9NE4xPDlizszNMi=> NVPEfmROOjJ3OEK5PVE>
human A549 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUHjfnAxUW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFkvPjZibl2= M1jnd3NCVkeHUh?=
human NCI-H1703 cell Mmi2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHq3THFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVcxOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR7LkixJI5O MY\TRW5ITVJ?
L1210 cell lines NUPzfpJTTnWwY4Tpc44h[XO|YYm= NVXwOGZNS2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JJJmeGyrY3H0bY9vKG:oIFyxNlExKGOnbHygcIlv\XNiYomgOVAmKGGodHXyJFczKGi{IHnuZ5Vj[XSrb36sJGVFPTB;MD6wOUDPxE1w NGXaNWoyPjV{MEK0
human K562 cells MYnDfZRwfG:6aXRCpIF{e2G7 NHKyOHhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{KGK7IGPSRkBie3OjeTygTWM2OD1yLkC1JO69VQ>? M3ewRVI1QTV4NUW2
human LB2241-RCC cell NFfkOWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4Hlc2lvcGmkaYTpc44hd2ZiaIXtZY4hVEJ{MkSxMXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTV3LkO0JI5O M3PTVnNCVkeHUh?=
human MLMA cell M2nXNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIjIUWJKdmirYnn0bY9vKG:oIHj1cYFvKE2OTVGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21OU42OSCwTR?= MWDTRW5ITVJ?
human P30-OHK cell NHjsWI9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHXDPVFKdmirYnn0bY9vKG:oIHj1cYFvKFB|MD3PTGsh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Pi53IH7N Ml\hV2FPT0WU
RPMI-6410 human leukemic lymphoblastoid cell lines MVvDfZRwfG:6aXRCpIF{e2G7 NFzpPIlEgXSxdH;4bYNqfHliYXfhbY5{fCCUUF3JMVY1OTBiaIXtZY4hdGW3a3XtbYMhdHmvcHjvZoxie3SxaXSgZ4VtdCCuaX7ld{whUUN3ME2wMlA3KM7:TR?= M4XkRVY5Ojd3NE[=
human HT-29 cells NVPEU5RyWHKxbHnm[ZJifGmxbjDhd5NigQ>? M4qxe2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGStNlkh[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkC2OkDPxE1w MUeyO|c5PDR7
human NCI-H510A cell MmLFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWjXe3RrUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUyOEFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14OD6yOkBvVQ>? MWTTRW5ITVJ?
human J-RT3-T3-5 cell NHHVRYxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml\lTY5pcWKrdHnvckBw\iCqdX3hckBLNVKWMz3UN{02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjhwNEKgcm0> NUPTOXNVW0GQR1XS
human VA-ES-BJ cell M4\a[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4XsWmlvcGmkaYTpc44hd2ZiaIXtZY4hXkFvRWOtRmoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04OS54NTDuUS=> MljwV2FPT0WU
human T-24 cell NETCZXBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVLx[oJxUW6qaXLpeIlwdiCxZjDoeY1idiCWLUK0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|gvPTZibl2= NGjqW|ZUSU6JRWK=
human NB69 cell NFHlTGNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFzRO4RKdmirYnn0bY9vKG:oIHj1cYFvKE6ENkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23PU41QCCwTR?= NIjZfmlUSU6JRWK=
human BALL-1 cells MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnrBNlQhcA>? NX7oU3Z7T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hSkGOTD2xJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCZU2StNUBie3OjeTygS2k2OD1yLkC4JO69VQ>? NVricphXOjJ{NkSxO|A>
HL60 cells NHnX[nNRem:uaX\ldoF1cW:wIHHzd4F6 MoXCTY4hfmm2cn:gbY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RicILvcIln\XKjdHnvckBw\iCKTE[wJINmdGy|LDDJR|UxRTBwMEig{txO MlPBNVI5Pzd3OUO=
human CTV-1 cell M33qTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1HuRmlvcGmkaYTpc44hd2ZiaIXtZY4hS1SYLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24OE44PCCwTR?= MYTTRW5ITVJ?
human MEL-JUSO cell NWDtd|F4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVj3fFhEUW6qaXLpeIlwdiCxZjDoeY1idiCPRVytTnVUVyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTh3Lke2JI5O NX\oeIZVW0GQR1XS
human MOLT-4 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYPFSI1YUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05QS54NzDuUS=> MXnTRW5ITVJ?
human leukemia cell line(CCRF-CEM) M3fvfmN6fG:2b4jpZ:Kh[XO|YYm= MWHJckB3cXS{bzDjfZRwfG:6aXPpeJkhd2ZiY3;tdI92dmS|IIfldoUh\GW2ZYLtbY5m\CCxbjDJcohq[mm2aX;uJI9nKGi3bXHuJIxmfWunbXnhJINmdGxibHnu[UhES1KILVPFUUktKEmFNUC9NE4xQSEQvF2u MYW4PVE4PjR3
human SW982 cell Mlr4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M33Ve2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25NU4zOyCwTR?= MoDoV2FPT0WU
human NCI-SNU-1 cell Mki4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkfKTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvU17VMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5Nige,:jDDJR|UxRTl4Lke3JI5O MWrTRW5ITVJ?
HeLa human cell lines MXLGeY5kfGmxbjDhd5NigQ>? M3TJRVE1PCCq MkDvWIhmKGOxbYDveY5lKHejczD0[ZN1\WRiaX6geol1em9iZn;yJIFvfGm2dX3vdkBi[3Srdnn0fUg2OCViaX7obYJqfGmxbjDv[kB1fW2xcjDj[YxtKGe{b4f0bEkh[WejaX7zeEBJ\UyjIHj1cYFvKGOnbHygcIlv\XNiYX\0[ZIhOTR2IHjyMEBKTDVyPUCuNUDPxE1? MUGzOlI2PzF2
human H460 cells M3TPVmZ2dmO2aX;uJIF{e2G7 NHyyWIEzPCCq M{HkV2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFi0OlAh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjedMg M4q5clIxOjFzNU[0
human HCT116 cells NYK0SnF{TnWwY4Tpc44h[XO|YYm= NH3vXIVCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlEh|ryP NHnOT2szODJzMUW2OC=>
human GP5d cell MoXGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmDNTY5pcWKrdHnvckBw\iCqdX3hckBIWDWmIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUCyJI5O NWi0XGFwW0GQR1XS
human SAS cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkPMTY5pcWKrdHnvckBw\iCqdX3hckBUSVNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMEeuOVchdk1? M4nlVnNCVkeHUh?=
human BFTC-905 cell  M3vKUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHnMOZBKdmirYnn0bY9vKG:oIHj1cYFvKEKIVFOtPVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTB6LkOxJI5O NHraW4dUSU6JRWK=
human LB1047-RCC cell NUP3dWVwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYXXNJdSUW6qaXLpeIlwdiCxZjDoeY1idiCOQkGwOFcuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUC4MlQzKG6P MonBV2FPT0WU
human BB65-RCC cell NXP0cI1ET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVjtcXdmUW6qaXLpeIlwdiCxZjDoeY1idiCEQk[1MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzMD6xPUBvVQ>? Mlj5V2FPT0WU
human KE-37 cell NFq1NmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUXyN|FmUW6qaXLpeIlwdiCxZjDoeY1idiCNRT2zO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyOC56NTDuUS=> NEDzNXdUSU6JRWK=
human NCI-H292 cell NXjjVFZyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlrKTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyPC5{IH7N NVnaVFYzW0GQR1XS
human HT-1080 cell M3HRTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEewcG9KdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOTRwNEegcm0> M2LvSnNCVkeHUh?=
human HL60 cells MX3DfZRwfG:6aXRCpIF{e2G7 NEHKPI01QCCq NWjjXZZ[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOTF6IN88US=> NXXreYFHOTl|MkGyN|Q>
human CAKI-1 cell NEHLeFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MljxS5Jwf3SqIHnubIljcXSrb36gc4Yh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JHdUXC1zIHHzd4F6NCCJSUWwQVAvOTJizszN NHXpe2ozOjJ4NEG3NC=>
human CAKI-1 cell NVT2ZZk4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVLSVHprUW6qaXLpeIlwdiCxZjDoeY1idiCFQVvJMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOjBibl2= MWXTRW5ITVJ?
human HMV-II cell NXXyXWZ{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWPJcohq[mm2aX;uJI9nKGi3bXHuJGhOXi2LSTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5 M2jybHNCVkeHUh?=
human ES8 cell MkfOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3nUdmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUKzMlk{KG6P M4TFZnNCVkeHUh?=
human NEC8 cell M3G1Tmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MontTY5pcWKrdHnvckBw\iCqdX3hckBPTUN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUO0MlIyKG6P MU\TRW5ITVJ?
human EW-1 cell M{DwXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlfzTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUO4MlYzKG6P M4Prc3NCVkeHUh?=
murine leukemia P388 MY\GeY5kfGmxbjDhd5NigQ>? MX\BcpRq[2GwY3XyJIFkfGm4aYT5JINienKrZXSgc5V1KGmwII\peJJwKGGpYXnud5QhdXW{aX7lJIxmfWunbXnhJHA{QDhuIFnDOVA:OC5zNDFOwG0> M2[xO|EyOzV4MUGw
human H-EMC-SS cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3\BRWlvcGmkaYTpc44hd2ZiaIXtZY4hUC2HTVOtV3Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPDVwMkigcm0> M1vjV3NCVkeHUh?=
human SNU638 cells MlXVR5l1d3SxeHnjxsBie3OjeR?= MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTUnU3OzhiY3XscJMh[nliU2LCJIF{e2G7LDDJR|UxRTBwMUWg{txO NULNcZlzOjR7NU[1OVY>
human COR-L105 cell NYS4foVkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH7iOnBKdmirYnn0bY9vKG:oIHj1cYFvKEORUj3MNVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTZyLkO5JI5O MVXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-mTOR / mTOR / p-S6K / S6K / p-AMPK / AMPK / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 24714637     


REH cells were incubated for the indicated time periods with cytarabine (3.2 μM) and the levels of phosphorylated/total mTOR, p70S6K, AMPK, Akt and ERK were determined by immunoblotting. The representative blots from three independent experiments are shown.

24714637
Growth inhibition assay
Cell viability; 

PubMed: 24714637     


REH cells were incubated in the presence of different concentrations of cytarabine and cell viability was determined by acid phosphatase assay after 24 h and 48 h. The data are mean ± SD values of triplicate measurements from a representative of three independent experiments (*p<0.05 compared to untreated cells). 

24714637
In vivo Cytarabine is highly effective against acute leukaemias, which causes the characteristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man. [4] Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity. [5]

Protocol

Kinase Assay:[1]
- Collapse

In Vitro Growth Inhibition Assay:

Stock solution of Cytarabine is prepared in absolute ethanol, and serial dilutions of Cytarabine are prepared. CCRF-CEM cells are suspended in RPMI medium supplemented with 10% FBS, 0.1% gentamicin, and 1% sodium pyruvate. The cells are suspended in their respective media to give 10 mL volumes of cell suspension at a final density of 3-6 × 104 cells/mL. Appropriate volumes of Cytarabine solution are transferred to the cell suspensions, and incubation is continued for 72 hours. The cells are spun down and resuspended in fresh Cytarabine -free medium, and final cell counts are determined. The data are analyzed by sigmoidal curve fitting of the cell count versus Cytarabine concentration, and the results are expressed as the IC50 (Cytarabine concentration that inhibits cell growth to 50% of the control value).
Cell Research:[2]
- Collapse
  • Cell lines: Rat leukemic cell lines RCL/0, RO/1 and K7 and human myelomonocytic leukemic U937
  • Concentrations: ~100 μM
  • Incubation Time: 24, 48 and 72 hours
  • Method: Cells are incubated in the presence of different concentrations of Cytarabine at 37 °C for 24, 48, and 72 hours. At the time of 20-, 44-, or 68-hour incubation in the presence of Cytarabine, 10 mL of cell proliferation reagent WST-1 solution is added. After 2- and 4-hour incubation with WST-1, cell metabolic activity is assessed with colorimetric changes quantified by measuring the absorbance in a spectrophotometer at 450 nm. And cell division times are calculated from eosin counting in parallel with viability assay
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: Brown Norway rat with myelocytic leukaemia
  • Formulation: Dissolved in phosphate-buffered saline (pH 7.0) just before use.
  • Dosages: 5 - 1000 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro Water 48 mg/mL (197.35 mM)
DMSO 1 mg/mL (4.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 243.22
Formula

C9H13N3O5

CAS No. 147-94-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04113616 Recruiting Drug: KRT-232|Drug: Cytarabine|Drug: Decitabine Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN) Kartos Therapeutics Inc. September 25 2019 Phase 1|Phase 2
NCT03878927 Recruiting Drug: CPX-351|Drug: Gemtuzumab Ozogamicin Acute Myeloid Leukemia Weill Medical College of Cornell University|Jazz Pharmaceuticals|Pfizer August 23 2019 Phase 1
NCT03896269 Recruiting Drug: Liposome-encapsulated Daunorubicin-Cytarabine Blasts 10-19 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|High Risk Chronic Myelomonocytic Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent High Risk Myelodysplastic Syndrome|Refractory Chronic Myelomonocytic Leukemia|Refractory High Risk Myelodysplastic Syndrome M.D. Anderson Cancer Center|National Cancer Institute (NCI) May 14 2019 Phase 1
NCT03348033 Enrolling by invitation Biological: Chronic Myeloid Leukemia + NK cell Chronic Myeloid Leukemia Hospital de Clinicas de Porto Alegre March 2019 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Cytarabine | Cytarabine supplier | purchase Cytarabine | Cytarabine cost | Cytarabine manufacturer | order Cytarabine | Cytarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID